Mark Germain work email
- Valid
- Valid
- Valid
- Valid
- Valid
Mark Germain personal email
Mark Germain phone numbers
Mark Germain is a Managing Director at The Aentib Group. He possess expertise in start ups, biotechnology, venture capital, licensing, technology transfer and 6 more skills. Colleagues describe him as "Mark is a versatile and detail oriented guy who has excellent leadership skills."
-
Managing DirectorThe Aentib GroupNew York, Ny, Us
-
Managing DirectorLunit Cancer ScreeningNew York, Ny -
Chairman Board Directors (Vice Chairman June 2018 - September 2019)Scinai Immunotherapeutics Ltd. Jun 2018 - PresentJerusalem, Jerusalem, IlScinai Immunotherapeutics Ltd. (Nasdaq: SCNI) is a biopharmaceutical company focused on developing, manufacturing and commercializing innovative products for the prevention and treatment of infectious diseases and other illnesses. Since its inception, the company has executed eight clinical trials including a seven country, 12,400 participant Phase 3 trial of its vaccine candidate and has built a state-of-the-art manufacturing facility for biopharmaceutical products. With highly experienced pharmaceutical industry leadership, BiondVax is developing a pipeline of proprietary "biobetter" nano sized antibodies (NanoAbs) in collaboration with the world recognized research institutions Max Planck and University Medical Center Gottingen. The "biobetter" NanoAbs work through validated targets, eliminating significant upfront cost, time and risk usually associated with new drug development, and leverage unique attributes to create differention for underserved patient populations. www.biondvax.com. -
Managing DirectorThe Aentib Group May 2014 - PresentNew York, Ny, UsManaging DirectorAENTIB.com2014 – PresentThe Aentib Group is a global boutique advisory and investment firm offering highly customized solutions to an exclusive set of corporate and private equity clients with the goal of creating high-impact and transformational value on every project.Aentib manages a portfolio of over 30 GP relationships. To date Aentib has designed and implemented over twenty private equity investment programs where there was both a financial and economic impact objectives.In total, Aentib has led the formation of venture capital, private equity and real assets investment programs with over $6 billion under management for banks, SWF's, corporate and state pension fund investors.We also create, fund and build new companies and new venture capital funds through our Aentib Ventures arm.
-
Advisor Lunit Inc./Member Of Board Of Directors Lunit UsaLunit Mar 2021 - PresentBoston, Massachusetts, Us
-
Co-Founder Numerous Biotech Companies (Alexion, Incyte, Neurocrine, Ariad, Chromadex, And Others)Self Employed - Serial Entrepeneur 1992 - PresentCo-founder/Director and/or Chairman or Co-Chairman of numerous biotech/tech companies (Alexion, Incyte, Neurocrine, Ariad, ChromaDex, Biotechnology General, Pharmos, Peptor, Pluristem, Collexis Holdings and others). Actively involved in formation of companies, recruiting management, financings, initiating and negotiating corporate partnering, technology licensing, M & A, and deciding on and implementing strategic decisions
-
Chairman Board Of DirectorsHerrontech May 2017 - PresentBoston, Massachusetts, UsHerron Tech has developed a breakthrough next generation software platform (SOAJS Enterprise) to deliver a total digitization framework that includes microservices management, API lifecycle management, multi-cloud orchestration, resource management, IT Ops automation, all with no coding or development, single pane-of-glass management, end-to-end functional integration and multi-tenant versions and platforms. This open source platform is updated continuously to seamlessly connect with the latest 3rd party platforms and environments, and as such provides durable agility and adaptability, with on premise and SaaS versions that accelerate time-to-value, while reducing costs and ensuring durable integration and inter-operation across the technology stack. Avoid multi-year, expensive and often failed efforts to transform from a legacy environment to a digital organization; no more delays, cost overruns, personnel disruptions and opportunity cost. Bring innovation in-house; reallocate resources away from IT fixes and into launching products and building value. -
Co-Founder; Member Board Of Directors (Feb 2000 - June 2015; Co-Chairman Feb 2000 - May 2010)Chromadex Feb 2000 - PresentLos Angeles, California, UsChromaDex is an integrated, global nutraceutical company devoted to improving the way people age. Its lead product is TRU NIAGEN (nicotinamide riboside), a natural precursor to NAD+, an essential constituent of robust mitochondrial function, energy production and cell signaling. ChromaDex's key shareholders include Mr. Li Ka-Shing (Chairman Emeritus of CK Hutchison Holdings/Hutchison Whampoa) and his affiliate Horizon Ventures, and Iconiq Capital, the global multi-family office representing, among others, Mark Zuckerberg. Through the relationship with Mr. Li Ka-shing and Horizon Ventures, Niagen is now being offered through A.S. Watson, a member of CK Hutchison Holdings. A.S. Watson is the largest international health and beauty retailer in Asia and Europe with over 13,300 stores in 24 markets. -
Member Of The Board Of Directors (Co-Chairman 2007-2009)Pluristem Therapeutics May 2007 - Jun 2022Haifa, IlPluristem is a clinical-stage biotherapy company using placental cells and a unique, proprietary, 3-D technology platform to develop cell therapies for conditions such as inflammation, muscle repair, ischemia, hematological disorders, or exposure to radiation.
Mark Germain Skills
Mark Germain Education Details
-
New York University School Of LawLaw
Frequently Asked Questions about Mark Germain
What company does Mark Germain work for?
Mark Germain works for The Aentib Group
What is Mark Germain's role at the current company?
Mark Germain's current role is Managing Director.
What is Mark Germain's email address?
Mark Germain's email address is mg****@****tib.com
What is Mark Germain's direct phone number?
Mark Germain's direct phone number is +194941*****
What schools did Mark Germain attend?
Mark Germain attended New York University School Of Law.
What are some of Mark Germain's interests?
Mark Germain has interest in Corporate Partnering, M&a.
What skills is Mark Germain known for?
Mark Germain has skills like Start Ups, Biotechnology, Venture Capital, Licensing, Technology Transfer, Life Sciences, Private Equity, Intellectual Property, Corporate Finance, Contract Negotiation, Mergers.
Who are Mark Germain's colleagues?
Mark Germain's colleagues are Martinal Quan, Ann Magee, Alexandre Pfund, Jessica Taylor.
Free Chrome Extension
Find emails, phones & company data instantly
Download 750 million emails and 100 million phone numbers
Access emails and phone numbers of over 750 million business users. Instantly download verified profiles using 20+ filters, including location, job title, company, function, and industry.
Start your free trial